Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab

BACKGROUND: In the FIRE-3 trial, overall survival (OS) was significantly longer in patients treated with FOLFIRI plus cetuximab (C-mab) than in those treated with FOLFIRI plus bevacizumab (Bev), but progression-free survival (PFS) was not significantly different. This may be associated with the deep...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Onco Targets Ther
Main Authors: Osumi, Hiroki, Matsusaka, Satoshi, Suenaga, Mitsukuni, Shinozaki, Eiji, Mizunuma, Nobuyuki
פורמט: Artigo
שפה:Inglês
יצא לאור: Dove Medical Press 2015
נושאים:
Original Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4532210/
https://ncbi.nlm.nih.gov/pubmed/26273206
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S87101
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים